Management Challenges in CLL

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Program Overview

Initial Case Presentation (2005)

Initial Case Presentation: Tumor Markers

Using Prognostic Markers in the Clinic

Using Biomarkers in Selecting Chemoimmunotherapy

Using Biomarkers in Selecting Novel Therapies

Using NGS to Detect Subclonal Mutations

Case Continued: Treatment With Chemotherapy

Case Continued: Treatment With Novel Agents

Bleeding-Related Events With Ibrutinib

Case Continued: Fluctuating Lymphocyte Count

Case Continued: Disease Progression

Case Continued: Bone Marrow Biopsy

Clinical Considerations in Assessing Disease Progression on Ibrutinib

Clinical Considerations When Switching to Venetoclax: Minimizing Risk for TLS

iwCLL Guidelines: Considerations for Revised Approach to Response/Disease Progression

Resistance to Ibrutinib: Mutations

Case Continued: Initiating Treatment With Venetoclax

Minimizing Risk for TLS

Goals of Therapy

Achieving MRD Negativity With Venetoclax

Response to Venetoclax Post Ibrutinib

CAR T-Cell Therapy Post Ibrutinib

Potential Treatment Options After a BCR Signaling Inhibitor

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)